Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | MK-5108 |
| Synonyms | |
| Therapy Description |
MK-5108 is a selective Aurora A kinase inhibitor, which inhibits cell proliferation (PMID: 20053775, PMID: 30027525). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| MK-5108 | VX-689|MK5018|MK 5108 | Aurka Inhibitors 27 | MK-5108 is a selective Aurora A kinase inhibitor, which inhibits cell proliferation (PMID: 20053775, PMID: 30027525). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| SMARCA4 inact mut | lung non-small cell carcinoma | sensitive | MK-5108 | Preclinical - Cell culture | Actionable | In a preclinical study, a non-small cell lung cancer cell line harboring an inactivating mutation in SMARCA4 demonstrated sensitivity to MK-5108 (VX-689) in culture (PMID: 28102363). | 28102363 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|